With a great deal of felicity and immense optimism, I write this October 2015 edition of Oviya MedSafe’s newsletter, from London!
Having spent most of October meeting several drug safety professionals in the UK, I realize that Oviya MedSafe as an organization is well-recognized in this part of the world too for our consistent commitment and continuous contribution to the discipline of pharmacovigilance.
Participating in the PIPA Annual Conference 2015 and interacting with Medical Information & Pharmacovigilance industry colleagues from the UK as well as from some other parts of Europe affably imparted me with quite a lot of new learning, which I will treasure.
UK Pharmacovigilance Day 2015, the conference which I chaired at London, was successful as expected and received very positive feedback. I had the opportunity to also moderate a panel discussion Pharmacovigilance Outsourcing Trends, Predictions and Advantages – A SWOT Analysis with eminent panelists, which was well-appreciated by the audience for its content and presentation. Please click here to view some photographs clicked during the event.
My invited talk on the topic “South India – an attractive and emerging global pharmaceutical hub” at the forthcoming UK South India Business Meet 2015, which has been organized by the British South India Council of Commerce at the UK Parliament, is something that I look forward to. I trust the points I have to share on this topic will be relevant and considered by the concerned stakeholders.
Given the developments that India has rolled out a USD 275.21 million (INR 1800 crores) plan for overhauling the country’s drug regulatory system and that the UK Medicines and Healthcare products Regulatory Agency (MHRA) and India’s Central Drugs Standard Control Organisation (CDSCO) have signed a pact to increase collaboration between the two countries in the area of medicines and medical devices with the aim of further improving public safety, I believe this is the right time for fostering further collaboration between India and the UK in the domain of pharmaceutical services too, of which outsourced pharmacovigilance services form the lion’s share.
At this juncture, I wish to profusely thank leading pharmaceutical industry news portals Life Science World and Pharmabiz for featuring news on my events in the UK. I am specifically grateful to News Today, a long-established English daily newspaper published in India, for having published my detailed interview in this regard. I also thank The Hindu, a renowned English daily newspaper, for reporting this news. Please click on the hyperlinked names of the news portals/newspapers to read the relevant media reports on their websites.
Last but not the least, I take the pleasure of inviting you to Singapore for the 6th Annual Pharmacovigilance Asia 2015 conference, for which Oviya MedSafe is an event partner. Please click here for details of the three sessions in which my colleagues and I will be presenting on interesting topics both from global and Asia Pacific region-specific perspectives.
Before signing off, I am glad to present to you a whitepaper titled The Top 5 Technologies Set to Transform Pharmacovigilance compiled by IQPC, the organizers of the 6th Annual Pharmacovigilance Asia 2015 conference at Singapore.
Looking forward to connect with you through our November 2015 newsletter,
With thanks & regards,
Dr J Vijay Venkatraman
MBBS, F. Diab., MBA, FPIPA (UK)
Managing Director & CEO,
Pharmacovigilance Consulting & Drug Safety Services
Coimbatore, India & London, UK
India Office: +91-422-2444442
UK Office: +44-8452-733839
Google Plus: plus.google.com/109414464810448488118/posts